Data completeness
1/8 — Limited
PROKETAZINE (carphenazine maleate) by Thayer Medical is clinical pharmacology dextromethorphan: dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or addictive properties.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROKETAZINE (Carphenazine Maleate) is an oral tablet combining dextromethorphan (antitussive) and promethazine (antihistamine/sedative) for cough and cold symptom management. The dextromethorphan component elevates the cough reflex threshold centrally, while promethazine provides H1 receptor blockade with sedative and antiemetic effects. This is a combination therapy targeting symptomatic relief in upper respiratory conditions.
Pre-Launch
Pre-launch stage indicates active commercialization planning; expect growth in commercial headcount (brand, field, marketing) as launch approaches.
Mechanism of Action
CLINICAL PHARMACOLOGY Dextromethorphan: Dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or addictive properties. The drug acts centrally and elevates the threshold for coughing. It is about equal to codeine in depressing the cough reflex. In…
Indications
Worked on PROKETAZINE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.